Response to the feasibility of Kreher et al's “Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors”

Katelyn J. Rypka, Noah Goldfarb, Matthew Mansh

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)e181-e185
JournalJournal of the American Academy of Dermatology
Volume89
Issue number4
DOIs
StatePublished - Oct 2023

Keywords

  • basal cell carcinoma
  • immunosuppression
  • inflammatory bowel disease
  • keratinocyte skin cancer
  • nonmelanoma skin cancer
  • primary skin cancer
  • psoriasis
  • rheumatoid arthritis
  • skin cancer screening
  • squamous cell carcinoma

PubMed: MeSH publication types

  • Letter
  • Comment

Cite this